Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Hirsch

Endocrinology, Diabetes & Metabolism Manhasset, NY Medical Doctor

NPI 1679533434 CMS profile 1236351

1155 Northern Blvd, Ste 201, Manhasset, NY 11030

Open in the dashboard

General payments

$746,453

1,039 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barbara Hirsch of Manhasset, NY is reported in the CMS Open Payments database as having received $746,453 across 1,039 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71,072 98
2024 General $120,241 183
2023 General $108,514 150
2022 General $118,800 140
2021 General $80,708 97
2020 General $96,737 139
2019 General $150,381 232

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Hirsch
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Barbara Hirsch were reported at $71,072. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Barbara Hirsch Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $150,381 $494 $123–$2,253 $163
2020 $96,737 $335 $85–$1,841 $114
2021 $80,708 $398 $88–$1,981 $132
2022 $118,800 $364 $88–$1,568 $149
2023 $108,514 $420 $113–$1,614 $160
2024 $120,241 $440 $121–$1,646 $164
2025 $71,072 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $487,495 634 payments
  2. Abbott Laboratories $163,870 215 payments
  3. Novo Nordisk Inc $67,098 85 payments
  4. Eli Lilly and Company $7,121 18 payments
  5. Janssen Pharmaceuticals, Inc $6,885 9 payments
  6. Merck Sharp & Dohme Corporation $4,800 7 payments
  7. CeQur Corporation $3,563 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,528 8 payments
  9. AbbVie, Inc. $2,112 10 payments
  10. Amgen Inc. $195 10 payments
  11. Other $786 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $501,653 423 payments
  2. Travel and Lodging $98,820 228 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $71,050 63 payments
  4. Consulting Fee $39,161 19 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $20,125 19 payments
  6. Food and Beverage $15,423 280 payments
  7. Education $137 5 payments
  8. Long term medical supply or device loan $85 2 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $222,806 263 payments
  2. TRULICITY $196,208 248 payments
  3. FreeStyle Libre 3 $78,100 102 payments
  4. RYBELSUS $33,604 44 payments
  5. FreeStyle Libre Pro Diabetes Care $30,352 32 payments
  6. FreeStyle Libre Pro Diabetes Care $25,363 35 payments
  7. Ozempic $16,999 33 payments
  8. FREESTYLE LIBRE $16,624 17 payments
  9. FreeStyle Libre 2 $11,608 18 payments
  10. Tresiba $9,327 8 payments
  11. Other $29,040 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

3,882

Median for Endocrinology: 1,959

Drug cost

$2,117,359

Median for Endocrinology: $890,201

Branded share of claims

59.1%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 440 $802,625
Ozempic Semaglutide Brand 178 $312,838
Jardiance Empagliflozin Brand 165 $232,673
Trulicity Dulaglutide Brand 101 $184,756
Prolia Denosumab Brand 56 $97,208
Glumetza Metformin Hcl Brand 14 $94,371
Januvia Sitagliptin Phosphate Brand 35 $50,977
Rybelsus Semaglutide Brand 13 $33,278
Synthroid Levothyroxine Sodium Brand 407 $28,389
Farxiga Dapagliflozin Propanediol Brand 17 $27,996

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$709,249

Of which drugs: $93,194

Medicare patients

587

Average age 75

Services billed

27,511

427 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
Arthritis 46%
Osteoporosis 35%
Ischemic heart disease 34%
Cancer 22%
Chronic kidney disease 17%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 43 4,321 $89,483
Vaccine for influenza for injection into muscle 90653 Office 23 23 $1,882
Vaccine for influenza for injection into muscle 90662 Office 21 22 $1,770

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$71,222 440 —
JARDIANCE
$45 165 —
Wegovy
$38 — —
CYCLOSET
$36 — —
RYBELSUS
$35 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

1,039 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record